Fusion protein based on Grb2-SH2 domain for cancer therapy

► Grb2 mediates EGFR signaling through binding to phosphorylate EGFR with SH2 domain. ► We generated fusion proteins containing 1 or 2 SH2 domains of Grb2 added with TAT. ► The one with 2 SH2 domains (TSSF) interfered ERK phosphorylation. ► TSSF significantly delayed the growth of EGFR overexpressing tumor in a mouse model.